High Precision Broadband Optical Spectrometers for Molten Salt Reactors
Explore the source record for details and available documents.
SEARCH · Engineering Papers
Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Summer 2023 Intern Poster Session
Explore the source record for details and available documents.
Accomplishments presentation for program's All Hands Meeting.
Presentation to be given at the annual review meeting for MPACT
Conference Abstract submission
DOE BES highlight slide for work performed and published under the DOE CEM initiative.
Additive manufacturing (AM) has the potential to revolutionize the manufacturing process and speed up deployment of advance nuclear reactors. However, more information is needed on preparing AM materials for extreme reactor environments to qualify AM materials for nuclear applications. This project studies the surface preparation of AM 316H stainless steel using acid pickling and reports a successful procedure for descaling heat-treated AM material.
Part 1 of 4 presentations summarizing programmatic research progress.
This presentation is an overview of NREL activities in thermal energy storage technologies.
NA
Radioisotopes play a vital role in nuclear medicine, enabling the performance of diagnostic procedures such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), in addition to innovative targeted therapies for selectively delivering cytotoxic radiation doses to tumor cells while minimizing damage to healthy tissue [1]. Beta emitting radionuclides such as 90Y and 131I find wide use in radio-immunotherapy, with the radiopharmaceuticals 90Y-ibritumomab tiuxetan (Zevalin®) and 131I-tositumomab (Bexxar®) having received FDA approval for treatment of non-Hodgkin’s lymphoma through targeting the CD20 surface receptor, which is commonly expressed in many B cell non-Hodgkin’s lymphoma subtypes [2, 3]. 90Y has also been successfully applied for treatment of brain tumors [4, 5] and liver cancer [6]. The favorable chelation chemistry of 90Y enables its use with a variety of ligands for the development of radiopharmaceuticals suitable for targeting different carcinoma types [1].
Slide deck for research highlight summaries for Thrust 2.
Presentation
Present joint efforts between INL and ANL.
Explore the source record for details and available documents.